<DOC>
	<DOC>NCT01973569</DOC>
	<brief_summary>To evaluate the inhibitory effect of progression, compared with placebo, in joint destruction by AMG 162 administered subcutaneously to rheumatoid arthritis patients</brief_summary>
	<brief_title>AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Patients With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment</brief_title>
	<detailed_description>To evaluate the inhibitory effect of progression, compared with placebo, in joint destruction by AMG 162 administered subcutaneously at a dose of 60 mg every 6 months or every 3 months for 12 months to rheumatoid arthritis patients</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Diagnosed with rheumatoid arthritis according to the American College of Rheumatology (ACR) criteria for rheumatoid arthritis classification (1987 revision) or the 2010 ACREULAR (The European League Against Rheumatism) classification criteria for rheumatoid arthritis Functional class IV according by the ACR revised classification (1991)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Denosumab</keyword>
	<keyword>RANKL</keyword>
	<keyword>RANK</keyword>
	<keyword>AMG 162</keyword>
	<keyword>joint damage</keyword>
</DOC>